Evidence map›Paper›PMID 33889375›Full record

ArticleRare tumors2021

A case of metachronous bilateral secretory carcinoma.

Jessica Burlile, Andrea Collins, Joaquin Garcia, Kristin Gendron, Danielle Cunningham, Robert Foote

Abstract readCase Reports
In one paragraph

Article in Rare tumors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jessica BurlileTransitional Residency, Providence Sacred Heart Medical Center, Spokane, WA, USA.ORCID https://orcid.org/0000-0001-8653-1045
Andrea CollinsMayo Clinic Alix School of Medicine, Rochester, MN, USA.
Joaquin GarciaDepartment of Pathology, Mayo Clinic, Rochester, MN, USA.
Kristin GendronDepartment of Otolaryngology, Fairview Health System, Woodbury, MN, USA.
Danielle CunninghamDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Robert FooteDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory carcinoma (SC) was first recognized as a distinct salivary malignancy in 2010. In the nine years since its recognition, there have been multiple reports of SC of the major and minor salivary glands, as well one case of tongue base involvement. Here we present the first reported case of bilateral SC. The first tumor, diagnosed before the recognition of SC, was classified as mucoepidermoid carcinoma. After the contralateral parotid tumor was diagnosed as SC in 2016, the two histologies were compared, and the mucoepidermoid carcinoma was reclassified as SC. In this report, we describe our patient's clinical course and review the SC literature, with a focus on pathologic diagnosis and clinical prognosis.

Indexed as

bilateral parotid cancermammary analogue secretory carcinomaparotid cancersalivary gland cancerSecretory carcinoma

Identifiers

PMID33889375
PMCPMC8040565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.